Thyroid Hormone Receptor beta Agonist international drug patents, generic suppliers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-002	Mar 14, 2024		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-001	Mar 14, 2024		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-003	Mar 14, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-002	Mar 14, 2024		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-001	Mar 14, 2024		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-003	Mar 14, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-002	Mar 14, 2024		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: June 29, 2026

The THR-β agonist space is concentrated around a small set of active programs targeting dyslipidemia, fatty liver disease, and cardiometabolic risk. The patent estate is fragmented across (i) thyroid hormone receptor beta selectivity, (ii) chemical entities and stereochemistry, (iii) prodrug and formulation approaches that improve liver exposure and tolerability, and (iv) method-of-use claims tied to lipid and liver endpoints. Exclusivity windows cluster in 2025-2035 for multiple franchises, with the highest generic/biosimilar risk tied to chemical-entity patent expiry and any Orange Book-listed formulation or use patents that survive.

Commercial dynamics are shaped by: (1) payer preference for oral, once-daily agents with clean tolerability profiles versus legacy thyroid hormone exposure; (2) evidence requirements for hard outcomes vs surrogate endpoints; (3) trial success in nonalcoholic steatohepatitis and MASH-adjacent populations where regulatory endpoints may be stricter; and (4) competitive pressure from next-generation selective THR-β agonists and combination strategies with statins, ezetimibe, GLP-1s, and bile-acid pathways.

Which thyroid hormone receptor beta agonist drugs are on the market, and what are the competitive dynamics?

Featured snippet: The THR-β agonist market is led by a limited number of approved or late-stage agents; competition is driven by liver-selective efficacy on LDL-C, triglycerides, and fatty liver biomarkers, plus reduced thyroid-stimulating hormone (TSH) suppression relative to nonselective thyroid hormone.

What are the key commercial drivers for THR-β agonists?

Oral chronic dosing, with differentiation on TSH and free T4 suppression.
Statin-intolerant or add-on positioning in dyslipidemia.
Hepatic endpoint credibility (ALT/AST, MRI-PDFF, fibrosis surrogates) supporting MASH/MASH-adjacent claims.
Safety in chronic use: atrial fibrillation risk mitigation via reduced systemic thyroid hormone activity.

How does clinical positioning affect market share?

Companies that win with “biomarker-to-clinical” translation can expand label breadth.
Programs that only show surrogate lipid improvements face payer scrutiny against generics and combination generics.

Competitive landscape by development lane

Dyslipidemia-led

Primary differentiation: LDL-C and ApoB reduction with minimal TSH suppression.
Primary competitor pressure: generic statins and ezetimibe plus GLP-1-driven metabolic improvements.

MASH/MASH-adjacent

Primary differentiation: liver fat reduction with tolerability sufficient for long-duration dosing.
Primary competitor pressure: GLP-1 class and FXR/TKRP FXR modulators; trial endpoints are more regulatory-risk heavy.

Combination-ready

THR-β agonists are often tested as add-ons due to complementary mechanisms: bile acid metabolism, lipid export, and hepatic fat.

What patents protect thyroid hormone receptor beta agonist drugs (chemical entities, formulations, and method-of-use)?

Featured snippet: THR-β patent protection typically spans composition-of-matter for the agonist scaffold, salts/prodrugs and stereoisomers, plus formulation and method-of-use patents tied to lipid and liver biomarkers.

How many patent families typically cover a THR-β agonist?

A typical THR-β program has:

1 to 3 core composition-of-matter families (compound and stereochemistry)
1 to 4 formulation/prodrug families (prodrug linkers, release profiles, salt forms, excipients, particle engineering)
2 to 6 method-of-use families (indications such as hyperlipidemia, hypertriglyceridemia, NASH/MASH, hepatic steatosis, and cardiovascular risk markers)
1 to 3 manufacturing-related families (process for synthesis, purification, and scale-up)

Which patent types are most enforceable?

Composition-of-matter patents are the primary enforceability lever for small-molecule THR-β agonists.
Formulation/use patents become decisive when chemical-entity patents have expired or when generic applicants route around by claiming non-infringing compounds but still practice the protected method or formulation.

What formulation patents matter for generic entry risk?

Extended-release or delayed-release dosage forms if they are operational for Tolerability (TSH suppression reduction) and sustained liver exposure.
Prodrug constructs that enable liver-selective pharmacokinetics can be harder to work around without re-inventing chemistry.

When do the key THR-β patents expire, and when do exclusivity periods end?

Featured snippet: For THR-β agonists, the practical “last day” for generic entry is usually driven by the latest composition-of-matter expiry plus any Orange Book-listed formulation and method-of-use patents. If exclusivity covers clinical trial grants, those can extend market protection beyond patent expiry.

How exclusivity timelines typically stack

Compound patent expiry sets the chemical entry boundary.
“Use” patents can delay Paragraph IV entry even if a generic uses a non-infringing compound, if it seeks FDA approval for a protected indication.
Formulation patents can block generic launch for specific dosage forms.
Regulatory exclusivity can extend before or after patent expiry depending on approval pathway.

What to look for on the Orange Book

Orange Book listed drug products tied to:
- active ingredient(s) and strength(s)
- dosage form and route
- patent number and patent type (composition, method, formulation)
The “last update” and listed expiration dates to identify the latest-expiring patent controlling launch.

Which companies are challenging THR-β agonists with Paragraph IV (ANDA) filings?

Featured snippet: Paragraph IV challenges usually target the latest Orange Book-listed patent (often formulation or method-of-use) and argue invalidity and/or non-infringement.

What Paragraph IV strategies are common in THR-β cases?

Filing an ANDA with a proposed label carve-out to avoid method-of-use patents.
Claiming that a proposed product uses non-infringing formulation approaches that fall outside process and excipient claims.
Challenging validity on obviousness or enablement when the claimed scaffold is close to prior thyroid hormone derivatives.

How to map litigation risk to patent type

Highest risk: when a method-of-use patent is tightly linked to the exact endpoints used in clinical trials.
Medium risk: formulation patents with narrow claim scope are easier to design around.
Lower risk: older process patents if a generic can switch to a new manufacturing route.

What patent litigation affects thyroid hormone receptor beta agonists, including settlements and consent judgments?

Featured snippet: THR-β patent litigation tends to settle around cross-licensing or non-at-risk launch dates tied to the expiration of the latest contested patent.

Settlement structures commonly seen

License to file/market at a date aligned to patent expiry.
Staged entry: partial label launch earlier, expanded label after additional patents expire.
Agreement terms that bind affiliates and cover combination products.

Litigation impact on generic timelines

A consent judgment can impose delayed entry beyond patent expiry if it includes additional unlisted patents or extends “carve-outs” across label language.
Court decisions can trigger immediate design-around opportunities if claims are invalidated.

What is the Orange Book status of THR-β agonists, and which patents are listed for each drug product?

Featured snippet: Orange Book status reveals the controlling patents for each marketed strength and dosage form. For THR-β agents, the controlling patents are often method-of-use and formulation, not just composition-of-matter.

How to interpret Orange Book for launch planning

Identify the latest expiration date among listed patents by:
- dosage form (tablet, capsule, oral solution)
- strength
Determine which patents are:
- composition-of-matter (often broad but earlier)
- formulation (often late)
- method-of-use (often late)
Note patent numbers tied to the NDA and listed “active ingredient.”

What launch-relevant gaps to check

Whether a generic applicant can avoid listed use patents via label carve-out.
Whether Orange Book lists “second medical uses” that match trial endpoints in label.

What formulations are protected by THR-β patents (salts, prodrugs, extended release)?

Featured snippet: Formulation IP is a key throttle point for generic entry, especially where liver-selective pharmacokinetics rely on prodrug chemistry or release profile control.

Salt and stereochemistry protection

Salt forms and stereochemical variants can be protected if they change solubility, stability, or in vivo exposure.
Generic route changes can create non-infringing alternatives but may affect bioequivalence.

Prodrug and delivery-system protection

Prodrug linkers can shift distribution toward hepatic metabolism and reduce systemic thyroid activity.
Claims often cover:
- specific prodrug structures
- synthetic methods to make them
- formulations with prodrug stability buffers

Extended-release and particle engineering

Sustained release can reduce peak TSH suppression by flattening systemic exposure.
Formulation claims can cover:
- polymer matrices
- coating compositions
- particle size distribution ranges

What method-of-use patents exist for THR-β agonists (dyslipidemia, NASH/MASH, hepatic steatosis)?

Featured snippet: Method-of-use patents frequently claim treatment of hypercholesterolemia/hypertriglyceridemia and fatty liver disorders at defined dosing regimens with biomarker endpoints.

Common claim scopes

Lowering LDL-C or ApoB in patients with dyslipidemia.
Reducing triglycerides and non-HDL cholesterol.
Improving liver fat content and transaminases in NAFLD/NASH/MASH.
Reducing cardiovascular risk markers with THR-β agonist dosing while limiting TSH suppression.

How generics attempt to avoid method-of-use infringement

Carving out indications or using a non-protected regimen.
FDA label strategy to limit approved claims to unprotected endpoints.

How does the patent strength of THR-β agonists compare across leading compounds?

Featured snippet: Patent strength is typically highest where multiple overlapping families exist across composition, formulation, and use, with late-expiring formulation/use patents. Weakness appears when core chemical patents are early and only broad method-of-use remains.

Patent estate scoring framework (practical)

Late expiry count: number of patents expiring after the earliest core expiry.
Claim diversity: composition plus formulation plus use.
Litigation history: whether contested patents survived.
Design-around feasibility: narrow formulation claims favor generic work-around.

Market exposure sensitivity

High exposure: products with long label breadth and multiple Orange Book-listed controlling patents.
Lower exposure: products with narrow labels or early patent expiry.

What generic entry risks exist for THR-β agonists, including design-around and label carve-outs?

Featured snippet: Generic entry risk is greatest when controlling composition-of-matter patents expire and remaining Orange Book patents can be avoided via label carve-out or non-infringing formulation.

Generic pathway constraints

ANDA requires showing bioequivalence and pharmaceutic equivalence for the specific dosage form.
If formulation patents cover the dosage form mechanics, a generic may need a distinct formulation route.

Design-around vectors

Different salt form or polymorph.
Alternative prodrug linker chemistry that changes release and metabolism.
Alternate excipient systems that avoid formulation claims while meeting bioequivalence.

How do THR-β agonists compare with other thyroid-targeting or lipid-lowering agents on IP and lifecycle strategy?

Featured snippet: Compared with nonselective thyroid hormone derivatives, THR-β agonists add selectivity and delivery-based IP layers that extend lifecycle protection beyond the base scaffold.

Where THR-β differs from adjacent modalities

Small-molecule IP: composition and delivery chemistry dominate.
Biological IP: not relevant unless the class is expanded into biologics; current THR-β agonists are small molecules.

Lifecycle implications

Stronger likelihood of late-expiring formulation and use patents tied to liver-selective endpoints.
Potential for label expansion creates more method-of-use claims to block generic label carve-outs.

Key takeaways

THR-β agonists sit at the intersection of small-molecule composition IP and delivery/formulation IP built around liver selectivity and tolerability.
Generic entry risk hinges on the latest Orange Book-listed patent for the specific dosage form and label indication: method-of-use and formulation patents are often the critical remaining barriers after compound expiry.
Competitive advantage depends on clinical differentiation that maps to label-relevant endpoints, which then become the basis for enforceable method-of-use claims.
Litigation and Paragraph IV challenges typically target the latest Orange Book patents; settlements often convert risk into timed entry via consent judgments or licensing.

FAQs

Which Orange Book patent types most often block generic THR-β agonists: composition, formulation, or method-of-use?
What label carve-out strategies do ANDA filers use to avoid method-of-use infringement for THR-β agonists?
How do prodrug and extended-release formulation patents affect ANDA bioequivalence and design-around options?
What features of THR-β clinical endpoints tend to drive enforceable method-of-use patent claims?
How do settlement terms in THR-β patent litigation typically change generic launch timing relative to patent expiry dates?

References

FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). FDA database (accessed via FDA Orange Book system).
FDA. Guidance for Industry: ANDA Submissions and the 505(j) Regulatory Pathway (ANDA eligibility and standards).
FDA. Drugs@FDA (approval history, regulatory review timelines, and labeling references for marketed products).